Business Wire

GlobalLogic Announces Partnership with Cybereason to Develop Advanced, Intelligent Cyber Protection Solutions

Share

GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Cybereason, the leader in operation-centric attack protection, to help develop its next-generation cyber security platform and services. Deployed by large enterprises, governments, and major cloud providers worldwide, Cybereason’s future-ready attack protection spans across endpoints, the enterprise, the cloud, and everywhere the defenders battle cyber criminals. The collaboration will draw on GlobalLogic’s broad and deep expertise in security and data management software across devices through to the cloud, including the integration of advanced artificial intelligence (AI).

The program is one of the largest won by GlobalLogic in this field to date. It requires quickly scaling to hundreds of specialized engineers supporting Cybereason’s development roadmap over the next year. This program scope highlights the market’s need for stronger, better cybersecurity as cloud use, network expansions and other technology usage continued their upward trend and surged during the pandemic.

“Cyber threats have become considerably more frequent and sophisticated in recent years. We’ve become dangerously more vulnerable in areas traditional security solutions could not adequately protect—the network and the cloud,” said Rajaram Radhakrishnan, CRO, GlobalLogic. “Having operated in the cybersecurity space for more than a decade, GlobalLogic has become adept at successfully responding to complex requirements. Cybereason is a premier example of a crucial innovator building disruptive defense solutions, redefining what government-grade protection can be. We are honored to now be a part of their team.”

Cybereason delivers the most comprehensive protection available on the market today, analyzing more than 23 trillion security-related events per week—five times the volume of any other market solution. Using its patented Malicious Operations (MalOps™) engine, Cybereason reveals the full attack story across every device, user identity, application, and cloud deployment. One of Cybereason’s key solutions delivering this capability is the company’s Extended Detection and Response (XDR) solution—a unified detection and response tool that thwarts malicious operations across the entire IT stack. XDR is one of the several advanced technologies that GlobalLogic’s team will help Cybereason develop and enhance through the partnership.

“Cybereason’ operation-centric security approach is helping defenders combat sophisticated and persistent threats to their organizations. While other companies have security analysts chasing alerts without offering valuable insight, Cybereason helps organizations around the world leverage our award-winning technology each day to outthink and outpace attackers,” said Sam Curry, Chief Security Officer, Cybereason. “GlobalLogic’s track record along with its responsiveness and collaborative approach to R&D stood out as major factors in finalizing our partnership. Together, we will deliver next-gen cyber defense solutions that will help technology users better control their sensitive data and operations—no matter where they reside.”

About GlobalLogic

GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

About Cybereason

Cybereason (www.cybereason.com) is the champion for today’s cyber defenders, providing operation-centric attack protection that unifies security from the endpoint to the enterprise, to everywhere the battle moves. The Cybereason Defense Platform combines the industry’s top-rated AI-powered detection and response (EDR and XDR), next-gen antivirus (NGAV), Anti-Ransomware Protection and Proactive Threat Hunting to deliver context-rich analysis of every stage of a MalOp™ (malicious operation). Cybereason is a privately held, international company headquartered in Boston with customers in more than 40 countries.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GlobalLogic, Inc. (Global)
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com

Cybereason
Bill Keeler
Senior Director, Global Public Relations
+1. 929.259.3261
bill.keeler@cybereason.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye